Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Pharvaris N.V. (NASDAQ:PHVS) have been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $40.5556.

PHVS has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday. Leerink Partners set a $38.00 price target on shares of Pharvaris in a research note on Wednesday, December 3rd. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research note on Wednesday, December 3rd. Finally, Morgan Stanley increased their price objective on Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, December 4th.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds have recently made changes to their positions in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Pharvaris in the second quarter valued at approximately $57,000. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Pharvaris in the 3rd quarter worth approximately $75,000. Public Employees Retirement System of Ohio boosted its stake in shares of Pharvaris by 39.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock valued at $156,000 after purchasing an additional 1,769 shares during the last quarter. Finally, Legal & General Group Plc increased its position in shares of Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the period.

Pharvaris Stock Performance

Shares of PHVS opened at $26.48 on Friday. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -8.25 and a beta of -2.79. Pharvaris has a 52 week low of $11.51 and a 52 week high of $29.80. The stock has a fifty day moving average of $24.81 and a 200-day moving average of $22.84.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. As a group, equities analysts forecast that Pharvaris will post -2.71 EPS for the current year.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.